Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hemogenyx (HEMO)

Price 1.65p on 26-04-2024 at 12:54:55
Change 0.065p 4.1%
Buy 1.68p
Sell 1.622p
Buy / Sell HEMO Shares
Last Trade: Sell 20,000.00 at 1.622p
Day's Volume: 1,566,410
Last Close: 1.585p
Open: 1.648p
ISIN: GB00BYX3WZ24
Day's Range 1.646p - 1.65p
52wk Range: 1.125p - 6.30p
Market Capitalisation: £22m
VWAP: 1.62746p
Shares in Issue: 1,342m

Recent Trades History Hemogenyx (HEMO)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 20,000 1.622p Ordinary
12:53:35 - 26-Apr-24
Buy* 300 1.6567p Ordinary
12:10:56 - 26-Apr-24
Buy* 5,922 1.68p SI Trade
11:57:23 - 26-Apr-24
Buy* 7,112 1.6545p Ordinary
11:52:20 - 26-Apr-24
Buy* 2,282 1.6567p Ordinary
11:27:30 - 26-Apr-24
Buy* 47,872 1.6545p Ordinary
11:17:01 - 26-Apr-24
Sell* 50,000 1.6232p Ordinary
11:07:23 - 26-Apr-24
Sell* 4,760 1.622p Ordinary
10:41:19 - 26-Apr-24
Buy* 6,026 1.6511p Ordinary
09:36:28 - 26-Apr-24
Buy* 120 1.6531p Ordinary
09:12:32 - 26-Apr-24

Share Price History for Hemogenyx

Time period:
to
Date Open High Low Close Volume

Share News for Hemogenyx

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout

25th Apr 2024 12:19

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

29th Feb 2024 14:04

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing. Read More

Hemogenyx shares rise on potential for CBR to treat brain diseases

16th Feb 2024 11:27

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases. Read More

Hemogenyx says CBR can be used intranasally to treat viral infections

14th Feb 2024 10:14

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections. Read More

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

9th Feb 2024 10:00

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month. Read More

FTSE 100 Latest
Value8,117.01
Change38.15

Login to your account

Forgot Password?

Not Registered